A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal

Bristol-Myers Squibb (BMS)

Status

Completed

Conditions

Renal Cell Carcinoma

Study type

Observational

Funder types

Industry

Identifiers

NCT05168436

CA209-9W6

Details and patient eligibility

About

The purpose of this observational study is to determine patients' and professionals' preferences for the characteristics (attributes) of the treatment for Renal cell carcinoma (RCC) in Spain and Portugal.

Full description

This study uses a literature review, qualitative (focus groups) and quantitative methods (discrete-choice experiment, DCE) to determine renal cell carcinoma (RCC) participants and oncologists' preferences. In this clinical trial, the study team will develop a survey consisting of comparisons of hypothetical treatment profiles (scenarios). Scenarios are presented to participants, and each participant chooses the most preferable.

Enrollment

105 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

Oncologists from Spain and Portugal will be identified by the promoter and invited to participate in the study in accordance with the inclusion criteria described below.

The oncologist is currently working in a Spanish or Portuguese public hospital.
The oncologist has at least 2 years of experience in the management of participants with Renal Cell Carcinoma (RCC).
The oncologist has agreed to participate in the study.

Participants with a diagnosis of RCC will be identified and recruited by the Principal Investigators of the study, taking into account the inclusion criteria described below.

The participant has been diagnosed with RCC for a minimum of 2 months before study inclusion.
The participant has received or is currently receiving pharmacological treatment for RCC;
The participant has provided the informed consent to participate in the study.
The participant must be able to read, understand and complete the survey instrument according to the judgment of the responsible physician.

Exclusion Criteria:

• Not applicable